Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 7 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
97 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
FOCUS PHARMA from Leuven, company number BE0846744870, closed financial year 2025 with a result of € -20,562 after tax. For that financial year FOCUS PHARMA recorded a gross margin of € -20,000 and equity of € -91,912. Compared with financial year 2024, the result moved from € -39,892 to € -20,562. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ -91,912
▼ € 20,562 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -20,562
▲ 48 % less loss than in 2024
Profit after tax over the fiscal year.
€ 780
▲ 46% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -153,912.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 99,571
▲ 32% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 8,338 | € -15,751 | € -39,181 | € -20,000 | ▲ € 19,181 |
| Profit after taxes | € 7,322 | € -16,733 | € -39,892 | € -20,562 | ▲ € 19,331 |
| Equity | € -14,725 | € -31,458 | € -71,350 | € -91,912 | ▼ € 20,562 |
| Total debts | € 18,321 | € 35,813 | € 75,526 | € 99,586 | ▲ 32% |
| Cash | € 1,779 | € 599 | € 535 | € 780 | ▲ 46% |
| Retained profit | € -76,725 | € -93,458 | € -133,350 | € -153,912 | ▼ € 20,562 |
| Balance sheet total | € 3,597 | € 4,356 | € 4,176 | € 7,674 | ▲ 84% |
Key figures of FOCUS PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to FOCUS PHARMA?
What happened at FOCUS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Marie Lemmens stepped down as director. NBB
- Peter Van Ruyskensvelde stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 20,562. Source: NBB ↗
- Marie Lemmens became a director. NBB
- Peter Van Ruyskensvelde became a director. NBB
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 7,322 profit in 2022 to € 20,562 loss in 2025.
Best year ever: 2022, with € 7,322 profit.
A new publication or filing at FOCUS PHARMA? We notify you, reason included.
Follow FOCUS PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
since 2024 · until 2030
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Interleuvenlaan 62
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 97 companies are registered at this address.
All companies at this address →SCHUT BELGIë
€ 33,349 gross margin · 2025
QUATTRO CLASSICS
€ 12,672 gross margin · 2025
Business Brewery
€ 385,638 gross margin · 2025
There
€ 487,247 gross margin · 2025
SWILLEN - NEESEN
+92 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0846.744.870
- VAT number
- BE 0846.744.870
- Registered office
- Interleuvenlaan 62, 3001 Leuven
- Names & denominations
- FOCUS PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 June 2012
- Peppol
- Active · Active since 15 Oct 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren
Vervaardiging van geneesmiddelen
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied